Modifications of cellular responses to epidermal growth factor (EGF) induced by tumor promoters and anti-promoters were examined. The effect of the promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) EGF binding was studied using mouse epidermal cells. Initially, TPA decreased EGF binding. However, when cells were incubated continuously in TPA plus a low concentration of EGF, more EGF bound to TPA-treated cells than to control cells. It was shown that the effects of TPA were partially reversible and that the greater amount of EGF bound to TPA-treated cells over controls after long-term incubation was due to larger amounts of whole EGF in the media of TPA-treated cells when cells have regained their ability to bind EGF. The ability of TPA to induce DNA synthesis synergistically with EGF may depend on the transient sparing of EGF from degradation and subsequent binding of the spared EGF. Fluocinolone acetonide (FA) and retinoic acid (RA) are potent anti-promoters able to induce increased EGF binding. The possibility that these compounds exerted their anti-promoting activities through offsetting TPA-induced EGF binding alterations was studied. Rat-1 fibroblasts were used to examine the effect of FA on TPA-mediated changes in EGF binding and EGF-induced ornithine decarboxylase (ODC) activity and DNA synthesis. Pretreatment with FA caused increased EGF binding and decreased ODC activity and DNA synthesis stimulated by high or low EGF concentrations. The glucocorticoid lowered ODC and DNA synthesis induced by EGF in combination with TPA to levels closer to control (EGF alone) levels. These data indicated that the anti-hyperplasiagenic effect of FA may be partially mediated through the EGF receptor. The effects of RA on EGF binding and EGF-induced cellular responses were examined in Rat-1 and Swiss 3T3 fibroblasts. Pretreatment with RA resulted in increased EGF binding to 3T3 cells only. However, RA treatment was able to enhance ODC activity in both cell lines. Retinoic acid binding protein was detected only in Rat-1 cells. It was therefore unlikely that the effects of RA on ODC induction were mediated by either altered EGF binding or the presence of CRABP. Experiments with 3T3 cells demonstrated that TPA alone was able to induce ODC activity. It is therefore possible that TPA exerts part of its tumor promoting action through the EGF receptor, but other sites of action also contribute to its promoting properties.

Thesis (Ph. D.)--University of Kentucky, 2002. / Title from document title page. Document formatted into pages; contains vii, 158 p. : ill. Includes abstract. Includes bibliographical references (p. 128-155).

Cancer chemoprevention uses noncytotoxic drugs or nutrients to prevent, retard, or delay carcinogenesis. The future of cancer chemoprevention depends on understanding key cellular growth and proliferation-controlling events, developing markers of molecular carcinogenesis, surrogate endpoint biomarkers, and targeted chemopreventive approaches.